An interventional study of vein of Marshall ethanol infusion and PVI using pulsed field ablation in Atrial Fibrillation (AF), sponsored by Beijing Anzhen Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-07.
Sponsored by Beijing Anzhen Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies in Atrial Fibrillation by Beijing Anzhen Hospital — 25 open to participants now, 26 under way, 1 of them phase 3. Atrial Fibrillation · Beijing Anzhen Hospital.
Among the 36 studies in Atrial Fibrillation by Beijing Anzhen Hospital, this one is the 15th largest by planned enrollment of the 24 interventional ones that give a count, is one of 11 that started in 2025, is one of 21 with no phase, reaches primary completion later than 9 of the 25 other live ones, and was the 22nd registered.
4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.
Browse Atrial Fibrillation studies →25 of the 36 studies in Atrial Fibrillation by Beijing Anzhen Hospital are open now, in 1 country. Recruiting first, the newest first:
Beijing Anzhen Hospital · Sites in China
Ages 80+
Beijing Anzhen Hospital · Sites in China
Ages 18+
Beijing Anzhen Hospital · Sites in China
Ages 18–75
Beijing Anzhen Hospital · Sites in China
Ages 18+
Beijing Anzhen Hospital · Sites in China
Ages 18+
By country, each count listing its studies:
Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 11 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 340 is above the median of 150 across 2,480 interventional studies indexed under Atrial Fibrillation.
Median enrollment 410 across the 24 interventional studies, 7,000 across the 12 observational. Of the 6 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Beijing Anzhen Hospital is the lead sponsor of 194 studies on the registry; 103 are open to participants now.
6 of the studies in Atrial Fibrillation by Beijing Anzhen Hospital that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07411170Beijing Anzhen HospitalWearable Device-Assisted Remote Management in Atrial Fibrillation Complicated by Heart Failure: WARM-HF Trial | 2026-12 |
| NCT07541339Beijing Anzhen HospitalSafety and Efficacy of Conscious Sedation Versus General Anesthesia in Pulsed-Field Ablation for Paroxysmal Atrial Fibrillation | 2026-12-01 |
| NCT06791629Beijing Anzhen HospitalPulsed Field Ablation Versus Radiofrequency Ablation for Persistent Atrial Fibrillation | 2026-12-15 |
| NCT06927908Beijing Anzhen HospitalCardiac Denervation in Aortic Arch Replacement | 2027-01-01 |
| NCT07095959Beijing Anzhen HospitalMarshall Vein Ethanol Infusion in Addition to Pulsed Electric Field Ablation Versus Pulsed Electric Field Ablation Alone for Paroxysmal Atrial Fibrillation | 2027-07-10 |
Add all 6 to your calendar (.ics) → With an account.
Among the 36 studies in Atrial Fibrillation by Beijing Anzhen Hospital, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The Marvel-PAF trial is an investigator initiated, multi-center, open-label, randomized trial, which aims to compare the effectiveness of vein of Marshall in addition to pulmonary vein isolation using pulsed field ablation in the treatment of paroxysmal atrial fibrillation. The primary endpoint is any atrial arrhythmias lasting ≥30s without AAD during 12 months after procedure excluding the 2-months blanking period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Able to understand the purpose of the study, willing to receive randomization of the ablation strategy, and able to be followed up as required, voluntarily participate in the study and signed a written .
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PVI will be performed with PFA first, then EIVOM will be performed to achieve potential cardiac autonomous nerve modulation while reinforce LPV isolation.
Procedure: vein of Marshall ethanol infusion · Procedure: PVI using pulsed field ablation
PVI will be performed with PFA only
Procedure: PVI using pulsed field ablation
After PFA, the coronary sinus venography will be acquired in search of VOM ostium. Then an over-the-wire balloon will be sent into the VOM and deflated with 4-6 atm. Selective VOM venography will be performed, followed by injection of 10ml 95% ethanol into the VOM.
Bilateral pulmonary vein antrum ablation using a pulsed field ablation
Any atrial arrhythmias lasting ≥30s without AAD during 12 months after procedure excluding the 2-months blanking period
Time frame: 12 months after procedure excluding the 2-month blanking period
Any atrial arrhythmias lasting ≥30s with or without AAD during 12 months after procedure excluding the 2-months blanking period
Time frame: 12 months after procedure excluding the 2-months blanking period
Any atrial flutter/atrial tachycardia lasting ≥30s during 12 months after procedure excluding the 2-months blanking period
Time frame: 12 months after procedure excluding the 2-months blanking period
Any atrial arrhythmias after multiple ablation with or without AADs
Time frame: 12 months after first procedure excluding the 2-months blanking period
AF burden
Total AF/AFL time devided by total monitoring time
Time frame: 12 months after procedure excluding the 2-months blanking period
procedural complications
Time frame: 30 days after the procedure
Change in quality of life
Assessed by AFEQT scale
Time frame: at baseline and 12 months after procedure
Plan to share: No — Individual data will be shared only upon reasonable request to the principal investigator
No publications or documents are linked to this record.
Started Jul 2025 (actual). Primary completion is estimated for Jul 2027, 23 months after the start.
Of 797 non-industry interventional studies with no phase under Atrial Fibrillation, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 59. This study's planned 23 months is below that.
Counting every sponsor, half of 1,052 studies reached it within 33 months; a quarter within 18 and three quarters within 54.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.